한글목차

신경 바이오마커 세계 시장은 2025년에는 96억 4,000만 달러에 달하고, 2032년에는 231억 2,000만 달러에 이를 것으로 예측됩니다. 2025-2032년의 CAGR은 13.3%를 나타낼 것으로 예상됩니다.

그림. 신경 바이오마커 시장 점유율(%), 2025년 지역별

신경 바이오마커는 정상적인 생물학적 과정과 병원성 과정의 객관적인 측정과 평가에 도움이 됩니다. 이들은 신경 질환의 검출, 위험 평가, 질병 진행 추적, 치료 개입에 대한 반응 측정에 도움이 됩니다. 알츠하이머병, 파킨슨병, 다발성 경화증과 같은 신경질환의 발생률 증가는 신뢰성 있는 신경 바이오마커 수요를 높일 수 있습니다. 게다가 신경질환에 대한 정밀의료나 동반진단의 개발에 주목받고 있는 것도 시장의 성장을 뒷받침하고 있습니다. 그러나 질병 생물학에 대한 이해가 제한되어 있고 바이오 마커 사용에 대한 합의가 얻어지지 않은 것이 시장 성장의 과제가되었습니다.

시장 역학

신경 바이오마커 세계 시장 성장은 주로 신경질환 세계의 유병률 증가에 의해 초래됩니다. WHO의 데이터에 따르면, 신경질환은 세계에서 10억 명 이상이 병을 앓고 있으며, 신경질환은 세계 질병 부담의 주요 요인이 되고 있습니다. 이러한 질병에 걸리기 쉬운 노인 증가는 수요를 끌어 올릴 수 있습니다. 제약 기업에 의한 바이오마커 연구 및 의약품 개발 투자 증가는 시장 성장을 가속할 수 있습니다. 그러나 표적 식별부터 상용화에 이르는 의약품 개발 비용이 높은 것은 신흥국 시장에 대한 바이오마커의 진입을 방해하고 있습니다. 진단 및 임상적 의사결정에서 바이오마커 사용에 대한 합의가 부족하면 시장 성장을 방해할 수 있습니다. 학제간 연구를 위한 관민 공동 연구 증가는 시장 성장 기회를 제공할 수 있습니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 신경바이오마커 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모(10억 달러)와 연간 평균 성장률(CAGR%)을 제공합니다.
• 또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시 및 승인, 시장 동향, 지역에 의한 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 매개변수를 바탕으로 세계 신경 바이오마커 시장의 주요 기업을 프로파일링합니다.
• 이 보고서에서 통찰을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 타이핑, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
• 신경 바이오마커 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 산업의 다양한 이해관계자를 지원합니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map (COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 규제 시나리오
• 인수와 제휴 시나리오
• 자금 조달 및 투자
• PEST 분석
• Porter's Five Forces 분석

제4장 세계의 신경 바이오마커 시장-코로나 바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부의 대처
• 시장에 대한 COVID-19의 영향

제5장 세계의 신경 바이오마커 시장, 바이오마커 유형별, 2020-2032년(10억 달러)

• 소개
• 인공눈물
• 이미징 바이오마커
• 대사체학 바이오마커
• 프로테옴 바이오마커
• 유전체학 바이오마커

제6장 세계의 신경 바이오마커 시장, 용도별, 2020-2032년(10억 달러)

• 소개
• 알츠하이머병
• 파킨슨병
• 다발성 경화증
• 자폐증 스펙트럼 장애
• 기타

제7장 세계의 신경 바이오마커 시장, 최종 사용자별, 2020-2032년(10억 달러)

• 소개
• 병원의 검사실
• 임상 진단센터
• 연구기관
• 기타

제8장 세계의 신경 바이오마커 시장, 지역별, 2020-2032년(10억 달러)

• 소개
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 프로파일
  • Thermo Fisher Scientific Inc.
  • Merck &Co., Inc.
  • Bio-Rad Laboratories, Inc.
  • AbbVie Inc.
  • QIAGEN NV
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Myriad RBM
  • Quanterix Corporation
  • PerkinElmer Inc.
  • Fujirebio
  • Alzheon, Inc.
  • Diagenic ASA
  • Psynova Neurotech Ltd
  • Banyan Biomarkers, Inc.
  • Cisbio Bioassays
  • Athena Diagnostics
  • Immuno-Biological Laboratories Co., Ltd.

제10장 분석가 추천

• 융성과 쇠퇴
• 일관형 기회 맵

제11장 섹션

• 참고문헌
• 조사 방법

영문목차

Global Neurological Biomarkers Market is estimated to be valued at USD 9.64 Bn in 2025 and is expected to reach USD 23.12 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2032.

Figure. Neurological Biomarkers Market Share (%), By Region 2025

Neurological biomarkers help in objectively measuring and evaluating normal biological and pathogenic processes. These aid in detecting neurological disorders, assessing risk, tracking disease progression, and measuring response to therapeutic interventions. Rising incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and others can boost demand for reliable neurological biomarkers. Furthermore, growing focus on development of precision medicine and companion diagnostics for neurological conditions can drive the market growth. However, limited understanding of disease biology and lack of consensus on use of biomarkers can pose challenge to market growth.

Market Dynamics:

Global neurological biomarkers market growth is primarily driven by rising prevalence of neurological disorders globally. According to the data from WHO, neurological disorders affect over a billion people worldwide with neurological conditions being a major contributor to the global burden of disease. Growing geriatric population, prone to these disorders, can boost demand. Higher investments in biomarker research and drug development by pharmaceutical players can drive the market growth. However, high cost of drug development from target identification to commercialization hampers newer biomarkers from entering the market. Lack of consensus on use of biomarkers in diagnosis and clinical decision-making can hamper the market growth. Increasing public private collaborations for interdisciplinary research can offer market growth opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global neurological biomarkers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neurological biomarkers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Qiagen, Thermo Fisher Scientific and Abbott Laboratories
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global neurological biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

• By Biomarker Type:
  • Artificial Tears
  • Imaging Biomarkers
  • Metabolomics Biomarkers
  • Proteomic Biomarkers
  • Genomics Biomarkers
• By Application
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorders
  • Others
• By End User
  • Hospital Laboratories
  • Clinical Diagnostic Centers
  • Research Organizations
  • Others
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Bio-Rad Laboratories, Inc.
  • AbbVie Inc.
  • QIAGEN N.V.
  • Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Myriad RBM
  • Quanterix Corporation
  • PerkinElmer Inc.
  • Fujirebio
  • Alzheon, Inc.
  • Diagenic ASA
  • Psynova Neurotech Ltd
  • Banyan Biomarkers, Inc.
  • Cisbio Bioassays
  • Athena Diagnostics
  • Immuno-Biological Laboratories Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Biomarker Type
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Neurological Biomarkers Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Neurological Biomarkers Market, By Biomarker Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Artificial Tears
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Imaging Biomarkers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Metabolomics Biomarkers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Proteomic Biomarkers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Genomics Biomarkers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Neurological Biomarkers Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Alzheimer's Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parkinson's Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Multiple Sclerosis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Autism Spectrum Disorders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Neurological Biomarkers Market, By End User, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Laboratories
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clinical Diagnostic Centers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Research Organizations
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Neurological Biomarkers Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Thermo Fisher Scientific Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bio-Rad Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • QIAGEN N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Siemens Healthineers AG
  • Myriad RBM
  • Quanterix Corporation
  • PerkinElmer Inc.
  • Fujirebio
  • Alzheon, Inc.
  • Diagenic ASA
  • Psynova Neurotech Ltd
  • Banyan Biomarkers, Inc.
  • Cisbio Bioassays
  • Athena Diagnostics
  • Immuno-Biological Laboratories Co., Ltd.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Section

• References
• Research Methodology
• About Us and Sales Contact